| Literature DB >> 32890516 |
David Martinez1, Gustavo J Sarria2, Daniel Wakefield3, Claudio Flores4, Sameeksha Malhotra5, Benjamin Li6, Michael Ehmann7, David L Schwartz8, Gustavo R Sarria9.
Abstract
PURPOSE: The impact of the COVID-19 pandemic on Latin American radiation therapy services has not yet been widely assessed. In comparison to centers in Europe or the United States, the scarcity of data on these terms might impair design of adequate measures to ameliorate the pandemic's potential damage. The first survey-based analysis revealing regional information is herein presented. METHODS AND MATERIALS: From May 6 to May 30, 2020, the American Society for Radiation Oncology's COVID-19 Survey was distributed across Latin America with support of the local national radiation therapy societies. Twenty-six items, including facility demographic and financial characteristics, personnel and patient features, current and expected impact of the pandemic, and research perspectives, were included in the questionnaire.Entities:
Mesh:
Year: 2020 PMID: 32890516 PMCID: PMC7462756 DOI: 10.1016/j.ijrobp.2020.06.058
Source DB: PubMed Journal: Int J Radiat Oncol Biol Phys ISSN: 0360-3016 Impact factor: 7.038
Participant countries
| Countries (N = 115 responses) | n | % |
|---|---|---|
| Argentina | 12 | 10.4 |
| Aruba | 1 | 0.9 |
| Bolivia | 2 | 1.7 |
| Brasil | 20 | 14.7 |
| Chile | 7 | 6.7 |
| Colombia | 15 | 13.0 |
| Costa Rica | 1 | 0.9 |
| Ecuador | 2 | 1.7 |
| El Salvador | 1 | 0.9 |
| Mexico | 30 | 26.1 |
| Panamá | 1 | 0.9 |
| Paraguay | 1 | 0.9 |
| Perú | 17 | 14.8 |
| República Dominicana | 3 | 2.6 |
| Venezuela | 2 | 1.7 |
What disease sites/treatments are currently being delayed? (N = 115 participants)
| Participants | N | % |
|---|---|---|
| Locally advanced breast | 4 | 3.5 |
| Small cell lung | 3 | 2.6 |
| NSCLC early stage SBRT | 3 | 2.6 |
| NSCLC locally advanced | 2 | 1.7 |
| Early stage definitive HN | 4 | 3.5 |
| Locally advanced definitive HN | 2 | 1.7 |
| Post-operative adjuvant HN | 8 | 7.0 |
| CNS—high-grade glioma | 2 | 1.7 |
| CNS—GBM | 3 | 2.6 |
| GI—Esophageal/gastric | 3 | 2.6 |
| GI—pancreas | 1 | 0.9 |
| GI—liver | 5 | 4.3 |
| GI—rectal | 2 | 1.7 |
| GI—anal | 2 | 1.7 |
| Bladder | 2 | 1.7 |
| Sarcoma | 2 | 1.7 |
| GYN—cervical | 4 | 3.5 |
| GYN—uterine | 9 | 7.8 |
| GYN—vagina/vulva | 2 | 1.7 |
| Palliative emergent | 1 | 0.9 |
| Oligometastatic SBRT | 8 | 7.0 |
| Cutaneous: melanoma | 6 | 5.2 |
| Lymphomas and leukemia | 5 | 4.3 |
| Pediatric high-grade CNS | 3 | 2.6 |
| Pediatric low-grade CNS | 13 | 11.3 |
| Pediatric solid tumor | 3 | 2.6 |
| Pediatric leukemia/lymphoma | 5 | 4.3 |
| None of the above | 20 | 17.4 |
Abbreviations: CNS = central nervous system; GBM = glioblastoma; GI = gastrointestinal; GYN = gynecologic; HN = head and neck; NSCLC = non-small cell lung cancer; SBRT = stereotactic body radiation therapy.
Most frequent results.
Fig. 1(A) Proportion of medical practitioners per center. (B) Proportion of radiation therapists per center. (C) Experienced scarcity of resources. (D) Impact on staff attendance.
Fig. 2(A) Impact on patient influx. (B) Impact on revenue. (C) Telemedicine adoption rates. (D) Current working facilities.